Show simple item record

dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorFaivre-Finn, Corinne
dc.date.accessioned2011-01-21T11:56:34Z
dc.date.available2011-01-21T11:56:34Z
dc.date.issued2010-11-22
dc.identifier.citationTreatment of limited small cell lung cancer: an old or new challenge? 2010: Curr Opin Oncolen
dc.identifier.issn1531-703X
dc.identifier.pmid21107256
dc.identifier.doi10.1097/CCO.0b013e328341ee4d
dc.identifier.urihttp://hdl.handle.net/10541/120153
dc.description.abstractPURPOSE OF REVIEW: This review highlights how progress has been made in treating limited small cell lung cancer and outlines current challenges to overcome for improved cure rates. RECENT FINDINGS: There is a rationale for the tumour, node, metastasis staging system to replace the current convention of limited versus extensive stage. Positron emission tomography may aid in staging but prospective validation in larger series of patients is needed. Cisplatin and etoposide chemotherapy has yet to be superseded by either newer cytotoxic drugs or targeted agents. More progress has been made for radiotherapy but questions of optimal dose, schedule, timing and treatment volume remain unanswered. SUMMARY: Concurrent chemoradiotherapy is associated with a one in four chance of cure. Two ongoing phase III trials have been designed to address the optimal radiotherapy regimen to combine with cisplatin and etoposide. Close collaboration between radiation and medical oncologists is needed to make further progress and to improve patient access to curative intent concurrent chemoradiotherapy regimens.
dc.languageENG
dc.language.isoenen
dc.subjectChemotherapyen
dc.subjectRadiotherapyen
dc.subjectSmall-Cell Lung Canceren
dc.subjectTargeted Agentsen
dc.titleTreatment of limited small cell lung cancer: an old or new challenge?en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, UK bDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK.en
dc.identifier.journalCurrent Opinion in Oncologyen
html.description.abstractPURPOSE OF REVIEW: This review highlights how progress has been made in treating limited small cell lung cancer and outlines current challenges to overcome for improved cure rates. RECENT FINDINGS: There is a rationale for the tumour, node, metastasis staging system to replace the current convention of limited versus extensive stage. Positron emission tomography may aid in staging but prospective validation in larger series of patients is needed. Cisplatin and etoposide chemotherapy has yet to be superseded by either newer cytotoxic drugs or targeted agents. More progress has been made for radiotherapy but questions of optimal dose, schedule, timing and treatment volume remain unanswered. SUMMARY: Concurrent chemoradiotherapy is associated with a one in four chance of cure. Two ongoing phase III trials have been designed to address the optimal radiotherapy regimen to combine with cisplatin and etoposide. Close collaboration between radiation and medical oncologists is needed to make further progress and to improve patient access to curative intent concurrent chemoradiotherapy regimens.


This item appears in the following Collection(s)

Show simple item record